SK142599A3 - Use of pentosan polysulfate or a pharmaceutically acceptable salt thereof - Google Patents

Use of pentosan polysulfate or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
SK142599A3
SK142599A3 SK1425-99A SK142599A SK142599A3 SK 142599 A3 SK142599 A3 SK 142599A3 SK 142599 A SK142599 A SK 142599A SK 142599 A3 SK142599 A3 SK 142599A3
Authority
SK
Slovakia
Prior art keywords
pps
pharmaceutically acceptable
dosage form
scarring
acceptable salt
Prior art date
Application number
SK1425-99A
Other languages
English (en)
Slovak (sk)
Inventor
Gary E Striker
Liliane J Striker
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25283204&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK142599(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of SK142599A3 publication Critical patent/SK142599A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1425-99A 1997-04-16 1998-04-10 Use of pentosan polysulfate or a pharmaceutically acceptable salt thereof SK142599A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/840,777 US20010005720A1 (en) 1995-06-07 1997-04-16 Method of treating chronic progressive vascular scarring diseases
PCT/US1998/007517 WO1998046237A1 (en) 1997-04-16 1998-04-10 Method of treating chronic progressive vascular scarring diseases

Publications (1)

Publication Number Publication Date
SK142599A3 true SK142599A3 (en) 2001-12-03

Family

ID=25283204

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1425-99A SK142599A3 (en) 1997-04-16 1998-04-10 Use of pentosan polysulfate or a pharmaceutically acceptable salt thereof

Country Status (17)

Country Link
US (1) US20010005720A1 (zh)
EP (1) EP0986392A4 (zh)
JP (1) JPH1149802A (zh)
KR (1) KR20010006511A (zh)
CN (1) CN1259871A (zh)
AR (1) AR008559A1 (zh)
AU (1) AU750182B2 (zh)
BR (1) BR9809396A (zh)
CA (1) CA2285950A1 (zh)
HU (1) HUP0003256A3 (zh)
IL (1) IL132389A0 (zh)
NO (1) NO995024L (zh)
NZ (1) NZ500527A (zh)
SK (1) SK142599A3 (zh)
TW (1) TW557213B (zh)
WO (1) WO1998046237A1 (zh)
ZA (1) ZA982246B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006039709A1 (en) * 2004-10-01 2006-04-13 Keryx Biopharmaceuticals, Inc. Methods using glycosaminoglycans for the treatment of kidney disease
WO2010103837A1 (ja) 2009-03-11 2010-09-16 ゼライス株式会社 アテローム性動脈硬化症の進行抑制薬・予防薬・血中コレステロール低下薬・機能性食品・特定保健用食品
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
MX2020002288A (es) 2016-08-31 2020-07-14 Oji Holdings Corp Metodo de produccion para xilooligosacarido acido y xilooligosacarido acido.
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
KR20240023711A (ko) 2017-05-31 2024-02-22 오지 홀딩스 가부시키가이샤 보습 외용제
MX2020002726A (es) 2017-09-12 2020-07-20 Oji Holdings Corp Polisulfato de pentosan y metodo para producir polisulfato de pentosan.
HUE062342T2 (hu) 2017-12-20 2023-10-28 Oji Holdings Corp Pentozán-poliszulfát, valamint pentozán-poliszulfátot tartalmazó gyógyszerek
WO2023070164A1 (en) * 2021-10-28 2023-05-04 Paradigm Biopharmaceuticals Ltd Treatment of heart failure with preserved ejection fraction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
HUP0003256A2 (hu) 2001-02-28
JPH1149802A (ja) 1999-02-23
US20010005720A1 (en) 2001-06-28
NZ500527A (en) 2001-10-26
CA2285950A1 (en) 1998-10-22
AU750182B2 (en) 2002-07-11
AU7248298A (en) 1998-11-11
HUP0003256A3 (en) 2001-12-28
WO1998046237A1 (en) 1998-10-22
CN1259871A (zh) 2000-07-12
KR20010006511A (ko) 2001-01-26
TW557213B (en) 2003-10-11
NO995024L (no) 1999-12-13
BR9809396A (pt) 2000-06-13
EP0986392A1 (en) 2000-03-22
NO995024D0 (no) 1999-10-15
AR008559A1 (es) 2000-01-19
IL132389A0 (en) 2001-03-19
ZA982246B (en) 1998-09-17
EP0986392A4 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
CN104244956B (zh) 使用环糊精的方法
US20070082868A1 (en) Seaweed extract composition for treatment of diabetes and diabetic complications
JPH09328431A (ja) 抗炎症活性を有する硫酸化ポリサッカライド
AU699012B2 (en) Method of treating chronic progressive vascular diseases
Anan et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation
SK142599A3 (en) Use of pentosan polysulfate or a pharmaceutically acceptable salt thereof
WO2021073249A1 (zh) β-NMN在制备脓毒症器官损伤的治疗、预防药物中的应用
JP2000309538A (ja) 子癇前症および関連疾患の新規治療法
Fang et al. Protective effect of irbesartan by inhibiting ANGPTL2 expression in diabetic kidney disease
RU2196589C2 (ru) Способ индукции рассасывания образовавшихся рубцов или фиброзных образований в кровеносных сосудах или в сосудистой сети млекопитающего
MXPA99009415A (en) Method of treating chronic progressive vascular scarring diseases
CZ9903669A3 (cs) Přípravky pro léčení chronického progresivního vaskulárního jizvení
EP1804810A1 (en) Methods using glycosaminoglycans for the treatment of kidney disease
CN114703280B (zh) Emcn在诊断和治疗糖尿病肾病中的应用
Li et al. Protective effect and mechanism of dexmedetomidine on lung injury in diabetic mice with myocardial ischemia reperfusion.
CN110604735B (zh) 一种治疗肝纤维化、硬皮病的化合物及其应用
Veitch Late Interventions in SNXRats Reveal a Disconnect between GFR and Proteinuria
JP2001520987A (ja) 糖尿病に関連する眼疾患治療用の医薬品製剤を製造するためのグリコサミノグリカンの使用
Net et al. Polyethylene glycol for use in the prevention of abdominal inflammatory diseases and/or associated diseases
CN111973588A (zh) 升麻素及其衍生物的新用途
WO2001093854A1 (en) Method for treating hyperglycemia
UA139145U (uk) Засіб з нефропротекторною та гіпоазотемічною дією
CN113143922A (zh) Dhc在制备动脉粥样硬化治疗制剂中的应用
CZ20001455A3 (cs) Použití glykosaminoglykanů pro přípravu farmaceutických přípravků pro léčení očních poruch spojených s diabetem
Garrison El Rasheid Zakaria, Paul J. Matheson, 2 Ryan T. Hurt, 3